Skip to main content

Advertisement

Table 1 Patient information and diagnostics summary

From: The use of leukocytes’ secretome to individually target biological therapy in autoimmune arthritis: a case report

Time since onset of disease 3 months 1 year 2 years 5 years 10 years 11 years
Clinical parameters
 DAS28 8.09 8.37 7.94 6.87 7.61 3.76
 DAS28-CRP 7.75 7.98 7.55 6.63 7.44 4.34
 Bone erosions at X-rays None None Yes Yes Yes Yes
Biological parameters
 ESR (mm, first hour; Nl < 20) 63 68 37 8 24 5
 CRP (mg/L; Nl < 10) 56 85 25 1 18 7
 Ferritin (μg/mL; Nl < 200) 347 314 202 141 165 Not evaluated
 Platelet count (Nl < 400 billion/L) 469 390 348 225 247 263
 RF Undetectable Undetectable Undetectable Undetectable Undetectable Undetectable
 Anti-CCP Undetectable Undetectable Undetectable Undetectable Undetectable Undetectable
 ANA Undetectable Undetectable Undetectable Undetectable Undetectable Undetectable
 Synovial fluid analysis   8.93 billion WBC/L 21.15 billion WBC/L 120.8 billion WBC/L   
   99% neutrophils 99% neutrophils 83% neutrophils   
Diagnosis Active early RA Active early RA Possible RA-like PsoA RA-like PsoA with bone erosions RA-like PsoA with bone erosions RA-like PsoA with bone erosions
Treatment prescribed Prednisone
Methotrexate
Hydroxychloroquine
Naproxen
Initial treatment + adalimumab (anti-TNF) Stop adalimumab; Initial treatment + abatacept (IgG1 Fc-CTLA-4) Initial treatment + abatacept (IgG1 Fc-CTLA-4) Stop abatacept; Initial treatment + ustekinumab (anti-IL-12/IL-23) Initial treatment + tocilizumab
Notes HLA-B27 absent
Treatment at visit: diclofenac
Sterile synovial fluid was removed by joint aspiration Sterile synovial fluid was removed by joint aspiration
Mother and maternal grandmother have psoriasis
An aunt and her son have inflammatory spondylarthritis
Appearance of psoriasis skin lesions
Sterile synovial fluid was removed by joint aspiration
Ustekinimab (anti-IL-12/IL-23) and secukinimab (anti-IL-17) were not authorized at the time
No improvement after 6 months treatment with ustekinumab
Stop ustekinumab
Enrollement in study to quantify cytokines in plasma and secreted by activated PBMCs
Tocilizumab (anti-IL-6) begun
 
  1. ANA antinuclear antibody, anti-CCP anti-cyclic citrullinated peptide, CRP C-reactive protein, DAS28 disease activity score of 28 joints, ESR erythrocyte sedimentation rate, Nl normal level, PsoA psoriatic arthritis, RA rheumatoid arthritis, RF rheumatoid factor, WBC white blood cells